FDA Breakthrough Leverage the FDA Breakthrough Designation and CE approval to position CardioRenal Systems as a high-potential partner for hospitals and surgeons seeking validated solutions for Acute Kidney Injury in cardiac surgery and ICU settings.

Global Adoption Target European and Middle Eastern markets where the technology already shows growing adoption, focusing on regional health systems, distributors, and key opinion leaders to accelerate commercialization.

Strategic Partnerships Exploit recent collaboration activity such as ties with Tasso Inc and related entities to propose joint ventures, research programs, and real-world evidence studies that expand use cases and data-driven outcomes.

Midmarket Growth With a revenue range of 1–10 million and a lean team, position value-based, scalable deployment packages to mid-size hospitals and regional centers that can benefit from acute kidney injury management without large enterprise sales cycles.

Competitive Edge Highlight clinically validated, Breakthrough-designated technology to differentiate from peers, and pursue procurement channels, clinical pilots, and reimbursement discussions that accelerate adoption against larger incumbents.